[Orlistat: medically induced malabsorption of the fat in the treatment of severe obesity].
Hendel
H W
HW
Klinisk fysiologisk nuklearmedicinsk afdeling, H:S Hvidovre Hospital. helle@hendel.dk
Andersen
T
T
D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D000075202:Contraindications; D004041:Dietary Fats / Q000008:administration & dosage / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D006801:Humans; D007783:Lactones / Q000008:administration & dosage* / Q000009:adverse effects / Q000737:chemistry; D008049:Lipase / Q000037:antagonists & inhibitors*; D000077403:Orlistat; D012307:Risk Factors
D019440:Anti-Obesity Agents; D004041:Dietary Fats; D004791:Enzyme Inhibitors; D007783:Lactones; D000077403:Orlistat; D008049:Lipase